Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

Robert O. Bonow*, Robert A. Harrington, Clyde W. Yancy

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

11 Scopus citations
Original languageEnglish (US)
Pages (from-to)1298-1299
Number of pages2
JournalJAMA cardiology
Volume2
Issue number12
DOIs
StatePublished - Dec 2017

Funding

completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this